Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell R Smith

Blood

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Blood|March 26, 2016
Ibrutinib: a force with a dark side?Mitchell R Smith
Blood|April 25, 2015
CCMCL1: a new model of aggressive mantle cell lymphomaXiaoxian Zhao, Selina Chen-Kiang, Shashirekha Shetty, et al.
Blood|January 25, 2014
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)Julie E Chang, Hailun Li, Mitchell R Smith, et al.
Blood|August 11, 2017
A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinibAllison M Winter, Daniel J Landsburg, Anthony R Mato, et al.
Blood|August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Blood|March 3, 2012
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphomaJohn P Leonard, Ann S LaCasce, Mitchell R Smith, et al.
Blood|May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCLMitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Blood|March 26, 2016
Ibrutinib: a force with a dark side?Mitchell R Smith
Blood|April 25, 2015
CCMCL1: a new model of aggressive mantle cell lymphomaXiaoxian Zhao, Selina Chen-Kiang, Shashirekha Shetty, et al.
Blood|January 25, 2014
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)Julie E Chang, Hailun Li, Mitchell R Smith, et al.
Blood|August 11, 2017
A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinibAllison M Winter, Daniel J Landsburg, Anthony R Mato, et al.
Blood|August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Blood|March 3, 2012
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphomaJohn P Leonard, Ann S LaCasce, Mitchell R Smith, et al.
Blood|May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCLMitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
Pageof 1